Sparsentan is a single molecule designed to selectively block the receptors of two pathways which are associated with kidney disease progression. The receptors are endothelin 1A and angiotensin II type 1.1
Endothelin I and angiotensin II have a role in kidney function decline by contributing to inflammation and fibrosis in the kidney, changes to the shape of podocytes, podocyte loss, and increased permeability of the glomerular filtration barrier.2 Endothelin I and angiotensin II are also vasoconstrictive, meaning they cause a narrowing of blood vessels and an increase in pressure in the glomeruli.
Proteinuria is a standard measure of disease activity, and a predictor of and contributor to disease progression in FSGS.3,4
The goal of the sparsentan program for FSGS is to develop a well-tolerated, safe and effective treatment that sustainably reduces proteinuria and protects the long-term health of kidneys in people living with FSGS.